Latest Lipid Therapeutics Stories
HEIDELBERG, Germany, June 22, 2011 /PRNewswire/ -- - Primary Endpoint Met Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).